RZLT
Rezolute Inc
NASDAQ · Biotechnology
$3.12
+0.20 (+6.85%)
Open$2.95
Previous Close$2.92
Day High$3.24
Day Low$2.94
52W High$21.98
52W Low$11.13
Volume—
Avg Volume636.7K
Market Cap289.31M
P/E Ratio—
EPS$-0.52
SectorBiotechnology
Analyst Ratings
Buy
16 analysts
Price Target
+456.1% upside
Current
$3.12
$3.12
Target
$17.35
$17.35
$11.58
$17.35 avg
$20.59
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.23M | 44.79M | 46.31M |
| Net Income | 4.09M | 3.84M | 4.53M |
| Profit Margin | 9.0% | 8.6% | 9.8% |
| EBITDA | 6.09M | 5.25M | 5.80M |
| Free Cash Flow | 2.47M | 3.54M | 3.43M |
| Rev Growth | +6.6% | +21.1% | +6.0% |
| Debt/Equity | 0.15 | 0.18 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |